Zai Lab (NASDAQ:ZLAB) Insider Sells $55,088.91 in Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) insider Rafael Amado sold 2,957 shares of the stock in a transaction on Friday, March 13th. The shares were sold at an average price of $18.63, for a total value of $55,088.91. Following the completion of the sale, the insider owned 44,757 shares in the company, valued at approximately $833,822.91. The trade was a 6.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Rafael Amado also recently made the following trade(s):

• On Wednesday, December 31st, Rafael Amado sold 10,787 shares of Zai Lab stock. The stock was sold at an average price of $17.43, for a total value of $188,017.41.

Zai Lab Price Performance

ZLAB stock opened at $18.83 on Thursday. The business’s 50-day moving average is $18.69 and its two-hundred day moving average is $22.84. The firm has a market capitalization of $2.12 billion, a P/E ratio of -11.70 and a beta of 0.85. Zai Lab Limited Unsponsored ADR has a 1 year low of $15.96 and a 1 year high of $44.34.

Zai Lab (NASDAQ:ZLAB) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.02). The company had revenue of $127.60 million for the quarter, compared to analyst estimates of $122.67 million. Zai Lab had a negative return on equity of 22.81% and a negative net margin of 38.15%. On average, analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Zai Lab stock. SG Americas Securities LLC lifted its stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,396 shares of the company’s stock after buying an additional 642 shares during the period. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 at the end of the most recent quarter. Institutional investors and hedge funds own 41.65% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a report on Wednesday. Zacks Research downgraded shares of Zai Lab from a “hold” rating to a “strong sell” rating in a research note on Friday, January 23rd. Jefferies Financial Group raised Zai Lab to a “strong-buy” rating in a report on Monday, January 19th. Cantor Fitzgerald decreased their price target on Zai Lab from $55.00 to $37.00 and set an “overweight” rating for the company in a report on Friday, February 27th. Finally, UBS Group began coverage on Zai Lab in a research report on Wednesday, January 7th. They set a “buy” rating and a $35.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $50.00.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.